Of the 10 patients with cancers other than colorectal and FBXW7 mutations, none (0%) had simultaneous KRAS mutations or APC mutations compared to 6/7 (86%) patients with KRAS mutations and 3/7 (43%) with APC mutations in the colorectal cancer group (p = 0.0006 and p = 0.022, respectively Table 3). This evidence concerns the gene KRAS and cancer.